NOTCH1 inhibition was demonstrated to reduce cancer stem-like cells and cancer self-renewal abilities in vitro and in vivo studies looking at HNSCC cell lines and, thus, provide a promising target for HNSCC management [77] though once again, most of this research remains in the early pre-clinical phase. The gene discussed is NOTCH1; the disease is cancer.